Cryo-Save Group N.V.: Board Change
June 19, 2014 - London
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces today that Mr. Walter van Pottelberge shall step down and resign as non-executive board member effective 30 June 2014. Mr. Van Pottelberge is also a member of the board of the Belgian bank Argenta which means that he has to comply with new Belgian banking legislation that limits the number of board memberships that he may hold, as a consequence of which he has to step down from the board of directors of Cryo-Save and a number of other companies. Mr. Van Pottelberge was appointed to the board of directors in October 2007 and has been the company's chairman since 2013.
Frédéric Amar, CEO, stated: "Walter van Pottelberge has played a very imported role within the company and we are very sorry he can no longer serve on our board. His judgment, financial acumen and deep interest in the culture of our firm have benefited our people and our shareholders. On behalf of the entire board, I would like to thank Walter van Pottelberge for the great contribution he has made as board member and chairman of Cryo-Save."
Walter van Pottelberge commented: "I have been with Cryo-Save for many years now, and I am truly saddened that I need to step down from its board. I am proud to have been involved in initiating the restructuring of the company's business, of which the upcoming name change to Esperite, the creation of the three business units and the secondary listing on Euronext Paris are very important elements, and I am confident that the company and its management will be successful in its implementation."
|Cryo-Save Group||+ 31 (0) 575 548 998|
|Frederic Amar, CEO|
About Cryo-Save (www.cryo-save.com/group)
Cryo-Save, the uncontested leader in stem cell cryo-preservation, stores more than 260,000 samples from umbilical cord blood and cord tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Cryo-Save has cryopreserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Switzerland, Portugal, Germany, Dubai, and South Africa.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cryo-Save Group N.V. via Globenewswire